Higher Symptom Burden More Likely to Improve With MPN Treatment
Analysis of data from 2 clinical trials sought to determine the effect on symptom burden of 2 common therapies for myeloproliferative neoplasms.
Diagnosis & Disease Information
How Can Lifestyle Factors Affect Myeloproliferative Neoplasms?
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
Myeloproliferative Neoplasms: What Your Patients Need to Know
Myeloproliferative neoplasms (MPN) are a rare form of blood cancer. Though most people don’t know a lot about, approximately 20,000 people develop MPNs each year. Here are the basics you can explain to a concerned patient.
Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Some Patients With AML Secondary to MPN May Benefit From Venetoclax in Combination With a Hypomethylating Agent
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Bone Fracture Risk Increased in Patients With Myeloproliferative Neoplasms
Retrospective analysis sought to determine incidence of hip and vertebral fractures in patients with MPN compared with that of the general population.
Interferon Alpha and Pegylated Interferon Alpha Can Be Safe, Effective for Treatment of Essential Thrombocythemia and Polycythemia Vera
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
Assessment of Organ Elasticity as a Surrogate for Bone Marrow Fibrosis in Myeloproliferative Neoplasms
Spleen stiffness was found to be correlated with the extent of bone marrow fibrosis, as well as clinical outcome, in patients with MPNs.
MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
- Loading...
Loading...
Next post in Myeloproliferative Neoplasms
Loading... 
Loading...